Heron Therapeutics (HRTX) | Stock Overview & Key Data
Heron Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $1.34
High: $1.42
on August 29, 2025
52 Week Range
Low: $1.04
High: $2.68
on November 12, 2024
on March 5, 2025
All-Time High: $1,290.00 on January 13, 1992
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$212.3M
EPS
-0.01
P/E Ratio (TTM)
-15.44
Forward P/E
178.00
P/B Ratio
-7.85
PEG Ratio
0.23
Div. Yield
N/A
ROE
40.36%
Beta
1.155
Debt to Equity
-6.48
Financial Highlights
Profitability
Gross Margin
73.50%
Operating Margin
-4.40%
Profit Margin
-0.62%
Returns and Earnings
Return on Assets (TTM)
0.34%
Return on Equity (TTM)
40.36%
EBITDA
$3.6M
Net Income (TTM)
$-931.0K
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.98
Quarterly Revenue Growth (YoY)
3.30%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Heron Therapeutics HRTX | 212.31M Micro-cap | -3.57% | -27.03% | -29.32% | -45.34% | -15.63% | -30.05% | -66.83% | -90.17% |
| Vertex VRTX | 99.55B Large-cap | -1.04% | -16.52% | -12.54% | -18.50% | -3.63% | -21.15% | 39.13% | 46.72% |
| Regeneron REGN | 62.21B Large-cap | -1.49% | 4.04% | -4.08% | -16.89% | -18.80% | -50.98% | 0.01% | 0.06% |
| Editas Medicine EDIT | 245.48M Micro-cap | -8.21% | -0.77% | 40.44% | 33.85% | 96.18% | -31.28% | -82.67% | -91.57% |
| Silence Therapeutics SLN | 244.20M Micro-cap | -10.09% | -22.42% | -19.02% | 6.89% | -33.10% | -74.80% | -54.58% | -75.33% |
| Alector ALEC | 237.85M Micro-cap | -6.75% | 45.96% | 65.49% | 43.29% | 24.34% | -55.49% | -77.53% | -81.06% |
Ownership & Short Interest
Insider Ownership
0.74%
Institutional Ownership
87.88%
Shares Short
33M
Short Ratio
16.99
Short % of Shares Outstanding
28.15%
Average 10-Day Volume
2M
Average 90-Day Volume
2M
Heron Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Heron Therapeutics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is HRTX's 52-week high and low?
- In the last 52 weeks, Heron Therapeutics reached a high of $2.68 (on March 5, 2025) and a low of $1.04 (on November 12, 2024).
- What is the market cap and P/E ratio for HRTX?
- Curious about Heron Therapeutics's size and valuation? Its market capitalization stands at 212.31M. When it comes to valuation, the P/E ratio (trailing twelve months) is -15.44, and the forward P/E (looking ahead) is 178.00.
- Does HRTX pay dividends? If so, what's the yield?
- As for dividends, Heron Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Heron Therapeutics's main competitors or similar companies to consider before investing?
When looking at Heron Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX99.55B Healthcare Biotechnology -21.15% 39.13% Regeneron
REGN62.21B Healthcare Biotechnology -50.98% 0.01% Editas Medicine
EDIT245.48M Healthcare Biotechnology -31.28% -82.67% Silence Therapeutics
SLN244.20M Healthcare Biotechnology -74.80% -54.58% Alector
ALEC237.85M Healthcare Biotechnology -55.49% -77.53% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Heron Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Heron Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 40.36%, the Debt to Equity ratio from the most recent quarter is -6.48, and its Gross Profit Margin stands at 73.50%.
- What is the recent revenue and earnings growth for HRTX?
- Looking at Heron Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $150M. Compared to the same quarter last year (YoY), quarterly revenue grew by 3.30%, and quarterly earnings saw a YoY growth of N/A.
- How much of HRTX stock is held by insiders and institutions?
- Wondering who owns Heron Therapeutics stock? Company insiders (like executives and directors) hold about 0.74% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 87.88%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.